

CITATION REPORT

List of articles citing

Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study

DOI: 10.1111/liv.12818
Liver International, 2015, 35, 2155-66.

Source: <https://exaly.com/paper-pdf/60253688/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
660	TIMP-1 mediates TGF- β -dependent crosstalk between hepatic stellate and cancer cells via FAK signaling. 2015 , 5, 16492		36
659	GIT1 is a novel prognostic biomarker and facilitates tumor progression via activating ERK/MMP9 signaling in hepatocellular carcinoma. 2015 , 8, 3731-42		11
658	The Subtle Balance between Lipolysis and Lipogenesis: A Critical Point in Metabolic Homeostasis. 2015 , 7, 9453-74		239
657	Screening for hepatocellular carcinoma and cholangiocarcinoma: Can biomarkers replace imaging?. 2015 , 14, 128-138		7
656	Hepatocellular Carcinoma Occurs at an Earlier Age in Africans, Particularly in Association With Chronic Hepatitis B. 2015 , 110, 1629-31		42
655	Prognosis of advanced hepatocellular carcinoma: a new stratification of Barcelona Clinic Liver Cancer stage C: results from a French multicenter study. 2016 , 28, 433-40		31
654	Trends and Patterns of Hepatocellular Carcinoma Treatment in Korea. 2016 , 31, 403-9		8
653	A concise review of updated guidelines regarding the management of hepatocellular carcinoma around the world: 2010-2016. 2016 , 22, 7-17		199
652	New players in non-alcoholic fatty liver disease induced carcinogenesis: lipid dysregulation impairs liver immune surveillance. 2016 , 5, 511-514		
651	Circulating predictive and diagnostic biomarkers for hepatitis B virus-associated hepatocellular carcinoma. 2016 , 22, 8271-8282		29
650	Usefulness of staging systems and prognostic scores for hepatocellular carcinoma treatments. 2016 , 8, 703-15		21
649	Hepatocellular Carcinoma in Pakistan: National Trends and Global Perspective. 2016 , 2016, 5942306		17
648	Phase II trial of bevacizumab and erlotinib as a second-line therapy for advanced hepatocellular carcinoma. 2016 , 9, 773-80		14
647	Capitalising on improved rates of diagnosis of early hepatocellular carcinoma. 2016 , 64, 260-261		1
646	The impact of the revolution in hepatitis C treatment on hepatocellular carcinoma. 2016 , 27, 1467-74		42
645	Transarterial chemoembolization versus transarterial radioembolization in hepatocellular carcinoma: optimization of selecting treatment modality. 2016 , 10, 883-892		24
644	Distinctive features of hepatocellular carcinoma in non-alcoholic fatty liver disease. 2016 , 1, 156-164		73

643	Transarterial Chemoembolization for the Treatment of Advanced-Stage Hepatocellular Carcinoma. 2016 , 20, 2002-2009	22
642	Time for paradigm change in management of hepatocellular carcinoma: is a personalized approach on the horizon?. 2016 , 13, 455-467	10
641	Interobserver variability in gross tumor volume delineation for hepatocellular carcinoma : Results of Korean Radiation Oncology Group '1207 study. 2016 , 192, 714-21	8
640	Development and application of a fluorescence protein microarray for detecting serum alpha-fetoprotein in patients with hepatocellular carcinoma. 2016 , 44, 1414-1423	3
639	Comparison of hepatocellular carcinoma in Eastern versus Western populations. 2016 , 122, 3430-3446	150
638	Hepatocellular carcinoma. 2016 , 2, 16018	1274
637	Circulating Osteopontin and Prediction of Hepatocellular Carcinoma Development in a Large European Population. 2016 , 9, 758-65	29
636	Prognostic value of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with Barcelona Clinic Liver Cancer stages 0 and A hepatocellular carcinomas: a multicenter retrospective cohort study. 2016 , 43, 1638-45	27
635	Targeted Proteomics Predicts a Sustained Complete-Response after Transarterial Chemoembolization and Clinical Outcomes in Patients with Hepatocellular Carcinoma: A Prospective Cohort Study. 2017 , 16, 1239-1248	18
634	PEGylation potentiates hepatoma cell targeted liposome-mediated in vitro gene delivery via the asialoglycoprotein receptor. 2017 , 72, 293-301	1
633	Bridging locoregional therapy: Longitudinal trends and outcomes in patients with hepatocellular carcinoma. 2017 , 31, 136-143	6
632	Association of Provider Specialty and Multidisciplinary Care With Hepatocellular Carcinoma Treatment and Mortality. 2017 , 152, 1954-1964	116
631	Patterns and challenges of treatment sequencing in patients with hepatocellular carcinoma: Experience from a German referral center. 2017 , 32, 1730-1738	15
630	[Hepatocellular carcinoma]. 2017 , 58, 469-479	3
629	Immune oncology in hepatocellular carcinoma-hype and hope. 2017 , 389, 2448-2449	7
628	Chemoembolization for Hepatocellular Carcinoma in Patients with Extrahepatic Spread: Prognostic Determinants and Appropriate Candidates. 2017 , 28, 956-962	1
627	Potential ultrastructure predicting factors for hepatocellular carcinoma in HCV infected patients. 2017 , 41, 209-226	4
626	Should AFP (or any biomarkers) be used for HCC surveillance?. 2017 , 16, 137-145	18

625	NIACE score for hepatocellular carcinoma patients treated by surgery or transarterial chemoembolization. 2017 , 29, 706-715	12
624	Factors Influencing Surveillance for Hepatocellular Carcinoma in Patients with Liver Cirrhosis. 2017 , 6, 126-136	18
623	External radiation or ablation for solitary hepatocellular carcinoma: A survival analysis of the SEER database. 2017 , 116, 307-312	10
622	Early treatment response to transcatheter arterial chemoembolization is associated with time to the development of extrahepatic metastasis and overall survival in intermediate-stage hepatocellular carcinoma. 2017 , 79, 81-88	6
621	Anti-angiogenics in Hepatocellular Cancer Therapy. 2017 , 1-12	
620	Early Age Hepatocellular Carcinoma Associated With Hepatitis B Infection in South America. 2017 , 15, 1631-1632	16
619	Global trends in the burden of liver cancer. 2017 , 115, 591-602	29
618	Higher dietary intakes of choline and betaine are associated with a lower risk of primary liver cancer: a case-control study. 2017 , 7, 679	19
617	The treatment of intermediate stage tumours beyond TACE: From surgery to systemic therapy. 2017 , 67, 173-183	106
616	Sorafenib for the Treatment of Advanced Hepatocellular Cancer - a UK Audit. 2017 , 29, 256-262	18
615	Synergistic Combination for Chemoprevention of Hepatocellular Carcinoma: An In Silico and In Vitro Approach. 2017 , 120, 532-540	3
614	Dexamethasone Prophylaxis to Alleviate Postembolization Syndrome after Transarterial Chemoembolization for Hepatocellular Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled Study. 2017 , 28, 1503-1511.e2	20
613	Transarterial infusion of epirubicin and cisplatin combined with systemic infusion of 5-fluorouracil transarterial chemoembolization using doxorubicin for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a retrospective analysis. 2017 , 9, 615-626	6
612	Does Sorafenib Fit for All?. 2017 , 284, 919-921	
611	Retrograde portal vein flow and transarterial chemoembolization in patients with hepatocellular carcinoma - a case-control study. 2017 , 52, 1398-1406	
610	MicroRNA pharmacogenomics based integrated model of miR-17-92 cluster in sorafenib resistant HCC cells reveals a strategy to forestall drug resistance. 2017 , 7, 11448	21
609	Liver tissue classification in patients with hepatocellular carcinoma by fusing structured and rotationally invariant context representation. 2017 , 10435, 81-88	3
608	Characterization of the Immune Microenvironment in Hepatocellular Carcinoma. 2017 , 23, 7333-7339	76

607	Average treatment effect of hepatic resection versus locoregional therapies for hepatocellular carcinoma. 2017 , 104, 1704-1712		15
606	All-treatment array of hepatocellular carcinoma from initial diagnosis to death: observation of cumulative treatments. 2017 , 143, 2327-2339		5
605	Bridging to liver transplantation in HCC patients. 2017 , 402, 863-871		21
604	Noncirrhotic hepatocellular carcinoma: etiology and occult hepatitis B virus infection in a hepatitis B virus-endemic area. 2017 , 10, 529-536		17
603	Clinical outcomes of Y90 radioembolization for recurrent hepatocellular carcinoma following curative resection. 2017 , 44, 2195-2202		10
602	Sorafenib and 2,3,5-triiodobenzoic acid-loaded imageable microspheres for transarterial embolization of a liver tumor. 2017 , 7, 554		17
601	Microvascular invasion has limited clinical values in hepatocellular carcinoma patients at Barcelona Clinic Liver Cancer (BCLC) stages 0 or B. 2017 , 17, 58		26
600	A model predicting survival of patients with recurrent or progressive hepatocellular carcinoma: the MORE score. 2017 , 32, 651-658		2
599	Impact of country of birth on age at the time of diagnosis of hepatocellular carcinoma in the United States. 2017 , 123, 81-89		20
598	Experience from a real-life cohort: outcome of 606 patients with hepatocellular carcinoma following transarterial chemoembolization. 2017 , 52, 116-124		11
597	mRECIST response combined with sorafenib-related adverse events is superior to either criterion alone in predicting survival in HCC patients treated with TACE plus sorafenib. 2017 , 140, 390-399		12
596	The evolutionary scenario of hepatocellular carcinoma in Italy: an update. <i>Liver International</i> , 2017 , 37, 259-270	7.9	50
595	Reduced microperfusion due to portal vein thrombosis: Impact on the outcome of percutaneous thermal tumor ablation. 2017 , 67, 383-388		1
594	Treatment Stage Migration Maximizes Survival Outcomes in Patients with Hepatocellular Carcinoma Treated with Sorafenib: An Observational Study. 2017 , 6, 313-324		14
593	The prognostic value of inflammation-based scores in advanced hepatocellular carcinoma patients prior to treatment with sorafenib. 2017 , 8, 95853-95864		14
592	MicroRNA-526a targets p21-activated kinase 7 to inhibit tumorigenesis in hepatocellular carcinoma. 2017 , 16, 837-844		5
591	Conventional drug-eluting beads transarterial chemoembolization for hepatocellular carcinoma. 2017 , 9, 808-814		56
590	Green tea and the question of reduced liver cancer risk: the dawn of potential clinical relevance?. 2017 , 6, 122-126		3

589	Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma. 2018 , 69, 60-69	75
588	Adherence to Barcelona Clinic Liver Cancer therapeutic algorithm for hepatocellular carcinoma in the daily practice: a multicenter cohort study from Argentina. 2018 , 30, 376-383	9
587	Novel Albumin-Bilirubin Grade-Based Risk Prediction Model for Patients with Hepatocellular Carcinoma Undergoing Chemoembolization. 2018 , 63, 1062-1071	16
586	EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. 2018 , 69, 182-236	3196
585	LI-RADS for MR Imaging Diagnosis of Hepatocellular Carcinoma: Performance of Major and Ancillary Features. 2018 , 288, 118-128	63
584	Prognostic Performance of Ten Liver Function Models in Patients with Hepatocellular Carcinoma Undergoing Radiofrequency Ablation. 2018 , 8, 843	20
583	Staging for hepatocellular carcinoma in light of tumor heterogeneity: Time to change or update?. 2018 , 67, 2076-2078	3
582	Genomics Studies in Hepatocellular Carcinoma via Next-Generation Sequencing. 2018 , 49-68	1
581	Dual regulation of HMGB1 by combined JNK1/2-ATF2 axis with miR-200 family in nonalcoholic steatohepatitis in mice. 2018 , 32, 2722-2734	18
580	Surveillance for hepatocellular cancer. 2018 , 18, s66-s69	6
579	Comparison of twelve liver functional reserve models for outcome prediction in patients with hepatocellular carcinoma undergoing surgical resection. 2018 , 8, 4773	21
578	Hepatocellular carcinoma in South America: Evaluation of risk factors, demographics and therapy. <i>Liver International</i> , 2018 , 38, 136-143	7.9 33
577	LI-RADS and transplantation for hepatocellular carcinoma. 2018 , 43, 193-202	16
576	FOxAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma. 2018 , 67, 395-396	28
575	A randomized placebo-controlled trial of prophylactic dexamethasone for transcatheter arterial chemoembolization. 2018 , 67, 575-585	32
574	Combined resection and radiofrequency ablation versus transarterial embolization for intermediate-stage hepatocellular carcinoma: A propensity score matching study. 2018 , 117, 197-203	6
573	Impact of surveillance for hepatocellular carcinoma on survival in patients with compensated cirrhosis. 2018 , 68, 78-88	28
572	Rate of Nonsurveillance and Advanced Hepatocellular Carcinoma at Diagnosis in Chronic Liver Disease. 2018 , 52, 551-556	9

571	Hepatocellular carcinoma imaging systems: why they exist, how they have evolved, and how they differ. 2018 , 43, 3-12	35
570	Two BRM promoter polymorphisms predict poor survival in patients with hepatocellular carcinoma. 2018 , 57, 106-113	10
569	Liver transplantation beyond or downstaging within the Milan criteria for hepatocellular carcinoma. 2018 , 12, 265-275	13
568	Portal hypertension is associated with poor outcome of transarterial chemoembolization in patients with hepatocellular carcinoma. 2018 , 28, 2184-2193	22
567	Reply to: "Socio-economic deprivation significantly impacts clinical management and survival in hepatocellular carcinoma". 2018 , 68, 625	
566	Should we undertake surveillance for HCC in patients with NAFLD?. 2018 , 68, 326-334	93
565	Transarterial chemoembolization for hepatocellular carcinoma: development and external validation of the Munich-TACE score. 2018 , 30, 44-53	7
564	Hepatocellular carcinoma in the era of immunotherapy. 2018 , 42, 40-48	71
563	Outcomes of treatment with sorafenib in Egyptian patients with hepatocellular carcinoma: a retrospective cohort study. 2018 , 12, 99-107	4
562	Epidemiology of liver cancer in South Korea. 2018 , 24, 1-9	100
561	SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma. 2018 , 36, 1913-1921	310
560	Radioembolization in Advanced Hepatocellular Carcinoma. 2018 , 36, 1898-1901	7
559	Immunotherapy in the Asiatic population: any differences from Caucasian population?. 2018 , 10, S1482-S1493	23
558	Thioredoxin interacting protein promotes invasion in hepatocellular carcinoma. 2018 , 9, 36849-36866	11
557	circRNA of AR-suppressed PABPC1 91 bp enhances the cytotoxicity of natural killer cells against hepatocellular carcinoma via upregulating UL16 binding protein 1. 2019 , 17, 388-397	27
556	ACTG1 and TLR3 are biomarkers for alcohol-associated hepatocellular carcinoma. 2019 , 17, 1714-1722	7
555	Pretreatment Inflammation-Based Markers Predict Survival Outcomes in Patients with Early Stage Hepatocellular Carcinoma After Radiofrequency Ablation. 2018 , 8, 16611	19
554	Transcriptomic analysis of hepatocellular carcinoma reveals molecular features of disease progression and tumor immune biology. 2018 , 2, 25	21

553	Curcumin-loaded galactosylated BSA nanoparticles as targeted drug delivery carriers inhibit hepatocellular carcinoma cell proliferation and migration. 2018 , 13, 8309-8323	35
552	Prognosis of Spontaneous Bacterial Peritonitis in Hepatocellular Carcinoma Patients. 2018 , 33, e335	2
551	Radioembolization versus chemoembolization for unresectable hepatocellular carcinoma: a meta-analysis of randomized trials. 2018 , 11, 7315-7321	26
550	Management of Combined Hepatocellular Carcinoma-Cholangiocarcinoma. 2018 , 17, 385-391	
549	Impact of the Uridine?Cytidine Kinase Like-1 Protein and IL28B rs12979860 and rs8099917 SNPs on the Development of Hepatocellular Carcinoma in Cirrhotic Chronic Hepatitis C Patients-A Pilot Study. 2018 , 54,	2
548	Combination of transarterial chemoembolization and sorafenib improves outcomes of unresectable hepatocellular carcinoma: an updated systematic review and meta-analysis. 2018 , 48, 1058-1069	16
547	Pleiotropic Effects of Heparins: From Clinical Applications to Molecular Mechanisms in Hepatocellular Carcinoma. 2018 , 2018, 7568742	2
546	Indications and Best Practices for Intra-arterial Therapies to Treat Hepatocellular Carcinoma. 2018 , 17, 399-411	
545	The impact of antiviral therapy on hepatocellular carcinoma epidemiology. 2018 , 5, HEP03	11
544	A changing etiologic scenario in liver transplantation for hepatocellular carcinoma in a multicenter cohort study from Latin America. 2018 , 42, 443-452	11
543	Hepatocellular carcinoma among US and non-US-born patients with chronic hepatitis B: Risk factors and age at diagnosis. 2018 , 13, e0204031	6
542	Knockdown of ZNF233 suppresses hepatocellular carcinoma cell proliferation and tumorigenesis. 2018 , 679, 179-185	8
541	DNA topoisomerase 1 and 2A function as oncogenes in liver cancer and may be direct targets of nitidine chloride. 2018 , 53, 1897-1912	32
540	Local and Non-local Deep Feature Fusion for Malignancy Characterization of Hepatocellular Carcinoma. 2018 , 472-479	5
539	Role of Inflammasomes in the Development of Gastrointestinal Diseases. 2018 , 108, 235-268	1
538	Gastrointestinal Cancers-Carving Out the Optimal Local Therapies in the Gastrointestinal Tract. 2018 , 102, 233-242	
537	Anti-viral therapy is associated with improved survival but is underutilised in patients with hepatitis B virus-related hepatocellular carcinoma: real-world east and west experience. 2018 , 48, 44-54	17
536	Multimodality treatment of hepatocellular carcinoma: How field practice complies with international recommendations. <i>Liver International</i> , 2018 , 38, 1624-1634	7.9 16

535	Das hepatozelluläre Karzinom. 2018 , 13, 42-51	1
534	A Seven-Year Retrospective Study on the Surveillance of Hepatitis B in Laos. 2018 , 2018, 9462475	5
533	Screening therapeutic targets of ribavirin in hepatocellular carcinoma. 2018 , 15, 9625-9632	6
532	Efficacy and safety of sorafenib versus apatinib in the treatment of intermediate and advanced hepatocellular carcinoma: a comparative retrospective study. 2018 , 11, 3407-3413	15
531	Multicentric Assessment of the Hong Kong Liver Cancer Staging System in Chinese Patients Following Transarterial Chemoembolization. 2018 , 41, 1867-1876	1
530	Is it really the "dark side" of herbal medicine?. 2018 , 61, 1118-1119	
529	IL-6 and IL-8 Serum Levels Predict Tumor Response and Overall Survival after TACE for Primary and Secondary Hepatic Malignancies. 2018 , 19,	25
528	Tumor-targeting core-shell structured nanoparticles for drug procedural controlled release and cancer sonodynamic combined therapy. 2018 , 286, 74-84	41
527	Comparison of overall survival between antiviral-induced viral suppression and inactive phase chronic hepatitis B patients. 2018 , 25, 1161-1171	13
526	Tumor-suppressing miR-141 gene complex-loaded tissue-adhesive glue for the locoregional treatment of hepatocellular carcinoma. 2018 , 8, 3891-3901	13
525	Mutations in and nucleotide excision repair genes are correlated with prognosis of hepatitis B virus-associated hepatocellular carcinoma. 2018 , 9, 2678-2686	2
524	Epidemiology of non-alcoholic fatty liver disease-related hepatocellular carcinoma and its implications. 2018 , 2, 235-241	30
523	Effectiveness of drug-eluting bead transarterial chemoembolization versus conventional transarterial chemoembolization for small hepatocellular carcinoma in Child-Pugh class A patients. 2019 , 11, 1758835919866072	6
522	A global view of hepatocellular carcinoma: trends, risk, prevention and management. 2019 , 16, 589-604	1209
521	Is anatomical resection necessary for early hepatocellular carcinoma? A single institution retrospective experience. 2019 , 15, 2041-2051	7
520	Management of patients with hepatocellular carcinoma and portal vein tumour thrombosis: comparing east and west. 2019 , 4, 721-730	46
519	Antioxidant Versus Pro-Apoptotic Effects of Mushroom-Enriched Diets on Mitochondria in Liver Disease. 2019 , 20,	9
518	Determination of portal vein tumor thrombus blood supply using in vivo cellular magnetic resonance imaging in a rabbit model. 2019 , 11, 5523-5529	1

517	The Beneficial Roles of SIRT1 in Drug-Induced Liver Injury. 2019 , 2019, 8506195		17
516	Retrospective analysis of sorafenib efficacy and safety in Chinese patients with high recurrence rate of post-hepatic carcinectomy. 2019 , 12, 5779-5791		1
515	Sarcopenia Is a Negative Prognostic Factor in Patients Undergoing Transarterial Chemoembolization (TACE) for Hepatic Malignancies. 2019 , 11,		13
514	The early evaluation of ultrasound-guided iodine-125 interstitial implants for high-risk hepatocellular carcinoma. 2019 , 18, 733-739		1
513	Emerging agents and regimens for hepatocellular carcinoma. 2019 , 12, 110		45
512	Characteristics, aetiologies and trends of hepatocellular carcinoma in patients without cirrhosis: a United States multicentre study. 2019 , 50, 809-821		47
511	Incorporation of biochemical factors for survival analysis of transarterial chemoembolization in patients with hepatocellular carcinoma: A retrospective cohort study. 2019 , 47, 4862-4871		1
510	Discrepancy Steered Conditional Adversarial Network For Deep Feature Based Malignancy Characterization of Hepatocellular Carcinoma. 2019 ,		
509	Animal Models of Hepatocellular Carcinoma: The Role of Immune System and Tumor Microenvironment. 2019 , 11,		24
508	From Code to Bedside: Introducing Predictive Intelligence to Interventional Oncology. 2019 , 1, e190139		1
507	Survival benefits of computed tomography-guided thermal ablation for adrenal metastases from hepatocellular carcinoma. 2019 , 36, 1003-1011		4
506	Fluid shear stress induces cell migration and invasion via activating autophagy in HepG2 cells. 2019 , 13, 152-163		12
505	Treatment with metformin is associated with a prolonged survival in patients with hepatocellular carcinoma. <i>Liver International</i> , 2019 , 39, 714-726	7.9	28
504	Weighing the benefits of hepatocellular carcinoma surveillance against potential harms. 2019 , 6, 23-30		9
503	Evaluation Efficacy of Rhenium-188-Loaded Micro-particles for Radiotherapy in a Mouse Model of Hepatocellular Carcinoma. 2019 , 16, 1083-1091		1
502	ATDC promotes the growth and invasion of hepatocellular carcinoma cells by modulating GSK-3 β /Wnt/ β catenin signalling. 2019 , 46, 845-853		1
501	PIVKA-II level is correlated to development of portal vein tumor thrombus in patients with HBV-related hepatocellular carcinoma. 2019 , 14, 13		5
500	Diffusion-weighted imaging of hepatocellular carcinoma before and after transarterial chemoembolization: role in survival prediction and response evaluation. 2019 , 44, 2740-2750		7

499	Tumor Hypervascularity and hand-foot-skin reaction predict better outcomes in combination treatment of TACE and Sorafenib for intermediate hepatocellular carcinoma. 2019 , 19, 409	10
498	MicroRNA-34a suppresses aggressiveness of hepatocellular carcinoma by modulating , and Caspase-3. 2019 , 11, 2963-2976	15
497	Cost-Utility Analysis of Imaging for Surveillance and Diagnosis of Hepatocellular Carcinoma. 2019 , 213, 17-25	24
496	Acute severe lymphopenia by radiotherapy is associated with reduced overall survival in hepatocellular carcinoma. 2019 , 195, 1007-1017	17
495	Mac-2 Binding Protein Glycosylation Isomer as a Hepatocellular Carcinoma Marker in Patients With Chronic Hepatitis B or C Infection. 2019 , 3, 493-503	16
494	Detection of Novel Fusion Transcript VTI1A-CFAP46 in Hepatocellular Carcinoma. 2019 , 6, 11-27	1
493	Technical Aspects and Practical Approach Toward Same-Day Y90 Radioembolization in the Management of Hepatocellular Carcinoma. 2019 , 22, 93-99	9
492	Efficacy and safety of transarterial chemoembolisation with cone-beam CT in patients with hepatocellular carcinoma within the Milan criteria: a retrospective cohort study. 2019 , 74, 407.e19-407.e28	0
491	Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin in Hepatocellular Cancer with Extrahepatic Spread. 2019 , 30, 349-357.e2	11
490	Nomogram and Artificial Neural Network for Prognostic Performance on the Albumin-Bilirubin Grade for Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. 2019 , 30, 330-338	16
489	Dose escalation by intensity modulated radiotherapy in liver-directed concurrent chemoradiotherapy for locally advanced BCLC stage C hepatocellular carcinoma. 2019 , 133, 1-8	18
488	The prognostic and predictive value of the combination of the neutrophil-to-lymphocyte ratio and the platelet-to-lymphocyte ratio in patients with hepatocellular carcinoma who receive transarterial chemoembolization therapy. 2019 , 11, 1391-1400	15
487	Predictors of Radiation-Induced Liver Disease in Eastern and Western Patients With Hepatocellular Carcinoma Undergoing Proton Beam Therapy. 2019 , 105, 73-86	24
486	Whole tumor ablation of locally recurred hepatocellular carcinoma including retained iodized oil after transarterial chemoembolization improves progression-free survival. 2019 , 29, 5052-5062	7
485	Efficacy and safety of external-beam radiation therapy for hepatocellular carcinoma: An overview of current evidence according to the different target population. 2019 , 13, 10-22	15
484	Hepatocellular carcinoma macroscopic gross appearance on imaging: predictor of outcome after transarterial chemoembolization in a real-life multicenter French cohort. 2019 , 31, 1414-1423	2
483	Hepatocellular carcinoma in alcoholic and non-alcoholic fatty liver disease-one of a kind or two different enemies?. 2019 , 4, 72	18
482	Improving the malignancy characterization of hepatocellular carcinoma using deeply supervised cross modal transfer learning for non-enhanced MR. 2019 , 2019, 853-856	4

481	The predictive values of serum dickkopf-1 and circulating tumor cells in evaluating the efficacy of transcatheter arterial chemoembolization treatment on hepatocellular carcinoma. 2019 , 98, e16579	7
480	Mebendazole augments sensitivity to sorafenib by targeting MAPK and BCL-2 signalling in n-nitrosodiethylamine-induced murine hepatocellular carcinoma. 2019 , 9, 19095	26
479	An Albumin-Bilirubin (ALBI) Grade-based Prognostic Model For Patients With Hepatocellular Carcinoma Within Milan Criteria. 2019 , 42, 698-704	9
478	Sorafenib for Treatment of Hepatocellular Carcinoma: A Survival Analysis From the South American Liver Research Network. 2019 , 53, 464-469	14
477	Clinical significance of down-regulated HINT2 in hepatocellular carcinoma. 2019 , 98, e17815	2
476	Comparison of Microwave Ablation and Transarterial Chemoembolization for Single-Nodule Hepatocellular Carcinoma Smaller Than 5cm: A Propensity Score Matching Analysis. 2019 , 11, 10695-10704	2
475	Association of Platelet Count and Mean Platelet Volume with Overall Survival in Patients with Cirrhosis and Unresectable Hepatocellular Carcinoma. 2019 , 8, 203-217	31
474	Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence. 2019 , 72, 28-36	163
473	Therapeutic advances for patients with intermediate hepatocellular carcinoma. 2019 , 234, 12116-12121	20
472	Trends in hepatocellular carcinoma due to non-alcoholic fatty liver disease. 2019 , 13, 179-187	26
471	Transarterial Chemoembolization related to Good Survival for Selected Patients with advanced Hepatocellular Carcinoma. 2019 , 10, 665-671	9
470	Critical systematic review on hepatic resection and transarterial chemoembolization for hepatocellular carcinoma. 2019 , 15, 439-449	0
469	Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: The phase III STAII trial. 2019 , 70, 684-691	81
468	Sirolimus in Liver Transplant Recipients with Hepatocellular Carcinoma: An Updated Meta-Analysis. 2019 , 32, 632-641	13
467	Impact of Anatomical Resection for Hepatocellular Carcinoma With Microportal Invasion (vp1): A Multi-institutional Study by the Kyushu Study Group of Liver Surgery. 2020 , 271, 339-346	35
466	Treatment Patterns and Economic Burden by Lines of Therapy Among Patients with Advanced Hepatocellular Carcinoma Treated with Systemic Cancer Therapy. 2020 , 51, 217-226	7
465	The Model to Estimate Survival in Ambulatory Hepatocellular Carcinoma Patients Aids in the Decision for TACE Retreatment. 2020 , 54, 370-377	
464	Cancers in Taiwan: Practical insight from epidemiology, treatments, biomarkers, and cost. 2020 , 119, 1731-1741	30

463	Dose escalation in radiotherapy for incomplete transarterial chemoembolization of hepatocellular carcinoma. 2020 , 196, 132-141	9
462	Association of Prophylactic Anti-Hepatitis B Virus Therapy With Improved Long-term Survival in Patients With Hepatocellular Carcinoma Undergoing Transarterial Therapy. 2020 , 71, 546-555	7
461	Improved Local Tumor Control and Survival Rates by Obtaining a 3D-Safety Margin in Superselective Transarterial Chemoembolization for Small Hepatocellular Carcinoma. 2020 , 43, 423-433	4
460	Conventional Versus Small Doxorubicin-eluting Bead Transcatheter Arterial Chemoembolization for Treating Barcelona Clinic Liver Cancer Stage 0/A Hepatocellular Carcinoma. 2020 , 43, 55-64	14
459	Accurate prediction of responses to transarterial chemoembolization for patients with hepatocellular carcinoma by using artificial intelligence in contrast-enhanced ultrasound. 2020 , 30, 2365-2376	38
458	Prognostic factors in hepatocellular carcinoma patients undergoing transarterial chemoembolization and radioembolization: a retrospective study. 2020 , 32, 1036-1041	2
457	Diabetes and Hepatocellular Carcinoma: Incidence Trends and Impact of Liver Disease Etiology. 2020 , 10, 296-303	10
456	Current strategies for the treatment of intermediate and advanced hepatocellular carcinoma. 2020 , 82, 101946	54
455	Gender Matters: Characteristics of Hepatocellular Carcinoma in Women From a Large, Multicenter Study in the United States. 2020 , 115, 1486-1495	16
454	Chemerin Is Induced in Non-Alcoholic Fatty Liver Disease and Hepatitis B-Related Hepatocellular Carcinoma. 2020 , 12,	7
453	Effectiveness and safety of irreversible electroporation for recurrent hepatocellular carcinoma ineligible for thermal ablation after surgery. 2020 , 3, 151-155	1
452	Analyses of Intermediate-Stage Hepatocellular Carcinoma Patients Receiving Transarterial Chemoembolization prior to Designing Clinical Trials. 2020 , 9, 596-612	7
451	Treatment patterns and direct medical costs among patients with advanced hepatocellular carcinoma. 2020 , 36, 1813-1823	
450	Deep Learning Predicts Overall Survival of Patients With Unresectable Hepatocellular Carcinoma Treated by Transarterial Chemoembolization Plus Sorafenib. 2020 , 10, 593292	11
449	Role of selected criteria and preventive chemotherapy in tumor recurrence after liver transplantation. 2020 , 19, 378-383	1
448	LI-RADS 4 or 5 categorization may not be clinically relevant for decision-making processes: A prospective cohort study. 2020 , 19, 662-667	4
447	Efficacy and Safety of Ramucirumab in Asian and Non-Asian Patients with Advanced Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Individual Data Analysis of Two Randomized Studies. 2020 , 9, 440-454	7
446	The alpha-fetoprotein serum is still reliable as a biomarker for the surveillance of hepatocellular carcinoma in Indonesia. 2020 , 20, 215	6

445	Adjuvant apatinib treatment after resection of hepatocellular carcinoma with portal vein tumor thrombosis: a phase II trial. 2020 , 8, 1301	3
444	Imaging Changes and Clinical Complications After Drug-Eluting Bead Versus Conventional Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: Multicenter Study. 2021 , 217, 933-943	10
443	A Prognostic Model of 15 Immune-Related Gene Pairs Associated With Tumor Mutation Burden for Hepatocellular Carcinoma. 2020 , 7, 581354	15
442	Etiology of Hepatocellular Carcinoma: Special Focus on Fatty Liver Disease. 2020 , 10, 601710	22
441	Surgery versus external beam radiotherapy for hepatocellular carcinoma involving the inferior vena cava or right atrium: A systematic review and meta-analysis. 2020 ,	6
440	The Prognostic Comparison Between Hepatocellular Carcinoma with Portal Vein Tumor Thrombus and Bile Duct Cancer Thrombus After Liver Resection. 2020 , 12, 12077-12086	2
439	Molecular and Functional Roles of MicroRNAs in the Progression of Hepatocellular Carcinoma-A Review. 2020 , 21,	22
438	Clinical heterogeneity in patients with non-alcoholic fatty liver disease-associated hepatocellular carcinoma. 2020 , 14, 1025-1033	3
437	The clinical application of camrelizumab on advanced hepatocellular carcinoma. 2020 , 14, 1017-1024	5
436	Hepatocellular carcinoma in Ghana: a retrospective analysis of a tertiary hospital data. 2020 , 36, 43	3
435	Role of epigenetic alterations in aflatoxin-induced hepatocellular carcinoma. 2020 , 1, 41-50	2
434	Regulation of Glucose and Lipid Metabolism by Long Non-coding RNAs: Facts and Research Progress. 2020 , 11, 457	5
433	Systemic adjuvant treatment in hepatocellular carcinoma: tempted to do something rather than nothing. 2020 , 16, 2587-2589	7
432	Targeted therapy for hepatocellular carcinoma. 2020 , 5, 146	79
431	A Comparison of Biannual Two-Phase Low-Dose Liver CT and US for HCC Surveillance in a Group at High Risk of HCC Development. 2020 , 9, 503-517	8
430	New advances in the diagnosis and management of hepatocellular carcinoma. 2020 , 371, m3544	74
429	Clinical efficacy of external beam radiotherapy complementing incomplete transarterial chemoembolization for hepatocellular carcinoma. 2020 , 96, 1541-1549	1
428	Prognosis of Early-Stage Hepatocellular Carcinoma: Comparison between Trans-Arterial Chemoembolization and Radiofrequency Ablation. 2020 , 12,	6

427	Development of machine learning-based clinical decision support system for hepatocellular carcinoma. 2020 , 10, 14855	9
426	Crosstalk between lncRNA DANCR and miR-125b-5p in HCC cell progression. 2021 , 107, 504-513	4
425	Prognostic Performance of Albumin-Bilirubin Grade With Artificial Intelligence for Hepatocellular Carcinoma Treated With Transarterial Chemoembolization Combined With Sorafenib. 2020 , 10, 525461	7
424	Tivozanib in advanced inoperable hepatocellular carcinoma: considerations for patients with liver cirrhosis. 2020 , 8, 1530	
423	Clinical and survival outcomes after hepatectomy in patients with non-alcoholic fatty liver and hepatitis B-related hepatocellular carcinoma. 2021 , 23, 1113-1122	4
422	Current status and future directions of hepatocellular carcinoma-targeted nanoparticles and nanomedicine. 2021 , 18, 673-694	8
421	Identification of an RNA binding protein-related gene signature in hepatocellular carcinoma patients. 2020 , 26, 125	3
420	Prognostic implications of alcohol dehydrogenases in hepatocellular carcinoma. 2020 , 20, 1204	6
419	The (Eternal) Debate on Microwave Ablation Radiofrequency Ablation in BCLC-A Hepatocellular Carcinoma. 2020 , 34, 3421-3429	8
418	Recent Updates of Transarterial Chemoembolization in Hepatocellular Carcinoma. 2020 , 21,	35
417	Recurrence of Hepatocellular Carcinoma in Hepatitis C Virus (HCV) Liver Transplant Recipients Treated with Pretransplant Direct-Acting Antiviral (DAA) Therapy. 2020 , 7, 134-143	2
416	Prognostic Role of Time to Surgery in Hepatocellular Carcinoma at Barcelona Clinic Liver Cancer Stage 0-A. 2020 , 27, 3740-3753	1
415	Therapeutic benefits of combined sorafenib for intermediate hepatocellular carcinoma unresponsive to transarterial chemoembolization in a Chinese population. 2020 , 21, 462-467	
414	The Influence of Immune Heterogeneity on the Effectiveness of Immune Checkpoint Inhibitors in Multifocal Hepatocellular Carcinomas. 2020 , 26, 4947-4957	11
413	Surveillance for Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease: Universal or Selective?. 2020 , 12,	16
412	HKR3 regulates cell cycle through the inhibition of hTERT in hepatocellular carcinoma cell lines. 2020 , 11, 2442-2452	4
411	Risk Factors for Liver Function Deterioration after Transarterial Chemoembolization Refractoriness in Child-Pugh Class A Hepatocellular Carcinoma Patients. 2020 , 75, 147-156	1
410	Evaluation of transarterial chemoembolization refractoriness in patients with hepatocellular carcinoma. 2020 , 15, e0229696	5

409	Outcomes of liver resection for hepatocellular carcinoma in octogenarians. 2020 , 22, 1324-1329	2
408	Biomarkers of exposure and early effect in three contaminated sites of southern Italy: protocols for etiological epidemiological studies. 2020 , 10, e036160	4
407	Comparison of clinical features and outcomes between HBV-related and non-B non-C hepatocellular carcinoma. 2020 , 15, 11	11
406	Postembolization fever after transarterial chemoembolization is a sign of unfavorable therapeutic response in hepatocellular carcinoma patients. 2020 , 7, 83-92	1
405	A cost analysis of SIR-Spheres yttrium-90 resin microspheres versus tyrosine kinase inhibitors in the treatment of unresectable hepatocellular carcinoma in France, Italy, Spain and the UK. 2020 , 23, 593-602	5
404	Novel liver fibrosis model in <i>Macaca fascicularis</i> induced by thioacetamide. 2020 , 10, 2450	4
403	Treatment of Hepatocellular Carcinoma in the Precision Medicine Era: From Treatment Stage Migration to Therapeutic Hierarchy. 2020 , 72, 2206-2218	49
402	Validation of prognostic accuracy of MESH, HKLC, and BCLC classifications in a large German cohort of hepatocellular carcinoma patients. 2020 , 8, 444-452	5
401	Efficacy and Safety of Liver-Directed Concurrent Chemoradiotherapy and Sequential Sorafenib for Advanced Hepatocellular Carcinoma: A Prospective Phase 2 Trial. 2020 , 107, 106-115	10
400	A comprehensive evaluation of single nucleotide polymorphisms associated with hepatocellular carcinoma risk in Asian populations: A systematic review and network meta-analysis. 2020 , 735, 144365	6
399	Screening for Hepatocellular Carcinoma in HIV-Infected Patients: Current Evidence and Controversies. 2020 , 17, 6-17	6
398	Targeting angiogenesis for liver cancer: Past, present, and future. 2020 , 7, 328-335	24
397	Comparison of guidelines for diagnosis of hepatocellular carcinoma using gadoxetic acid-enhanced MRI in transplantation candidates. 2020 , 30, 4762-4771	3
396	The suppressing effects of VEGF-mediated angiogenesis at different administration sequences of apatinib and transarterial embolization .. 2020 , 9, 1133-1143	
395	Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference. 2021 , 73 Suppl 1, 158-191	63
394	Epidemiology of HPB malignancy in the elderly. 2021 , 47, 503-513	5
393	Apatinib prevents natural killer cell dysfunction to enhance the efficacy of anti-PD-1 immunotherapy in hepatocellular carcinoma. 2021 , 28, 89-97	7
392	Proton beam radiotherapy vs. radiofrequency ablation for recurrent hepatocellular carcinoma: A randomized phase III trial. 2021 , 74, 603-612	31

391	Treatment strategy of adding transcatheter arterial chemoembolization to sorafenib for advanced stage hepatocellular carcinoma. 2021 , 4, e1294	1
390	Two-dimensional parametric parenchymal blood flow in transarterial chemoembolisation for hepatocellular carcinoma: perfusion change quantification and tumour response prediction at 3 months post-intervention. 2021 , 76, 160.e27-160.e33	
389	Bone mesenchymal stem cells derived extracellular vesicles promote TRAIL-related apoptosis of hepatocellular carcinoma cells via the delivery of microRNA-20a-3p. 2021 , 30, 223-235	5
388	Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores. 2021 , 74, 775-782	50
387	Development and validation of a CTNNB1-associated metabolic prognostic model for hepatocellular carcinoma. 2021 , 25, 1151-1165	11
386	Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. 2021 , 18, 223-238	228
385	Published trials of TACE for HCC are often not registered and subject to outcome reporting bias. 2021 , 3, 100196	0
384	Prognosis Nomogram for Hepatocellular Carcinoma Patients with Portal Vein Invasion Undergoing Transarterial Chemoembolization Plus Sorafenib Treatment: A Retrospective Multicentre Study. 2021 , 44, 63-72	3
383	Hepatocellular carcinoma in Senegal: epidemiological, clinical and etiological aspects about 229 cases at. 2021 , 38, 99	4
382	Hyperprogression in a Patient With Hepatocellular Cancer Treated With Atezolizumab and Bevacizumab: A Case Report and Review of Literature. 2021 , 9, 2324709621992207	2
381	Therapeutic Guidelines for Patients with Liver Cancer from the Perspective of Radiation Oncologists. 2021 , 155-168	
380	Biochemical predictors of response to immune checkpoint inhibitors in unresectable hepatocellular carcinoma. 2021 , 27, 100328	33
379	Feasibility and Techniques of Securing 3D-Safety Margin in Superselective Transarterial Chemoembolization to Improve Local Tumor Control for Small Hepatocellular Carcinoma: An Intend-to-Treat Analysis. 2021 , 10, 63-71	1
378	Transarterial Chemoembolization Plus External Beam Radiotherapy. 2021 , 181-189	
377	Cost-Effectiveness of Imaging Tumor Response Criteria in Hepatocellular Cancer After Transarterial Chemoembolization. 2021 , 18, 927-934	1
376	The Influence and Prognostic Value of Iron Metabolic-Related Gene Signatures in Hepatocellular Carcinoma Patients. 2021 , 11, 3969-3982	
375	Hepatocellular Carcinoma in Pakistan: An Update. 2021 , 387-396	
374	A review of cutting-edge therapies for hepatocellular carcinoma (HCC): Perspectives from patents. 2021 , 18, 3066-3081	5

373	Scutebarbatine A induces cytotoxicity in hepatocellular carcinoma via activation of the MAPK and ER stress signaling pathways. 2021 , 35, e22731		1
372	ALBI score and outcomes in patients with hepatocellular carcinoma: analysis of the randomized controlled trial KEYNOTE-240. 2021 , 13, 17588359211039928		2
371	Time-Varying mHAP-III Is the Most Accurate Predictor of Survival in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. 2021 , 10, 126-136		3
370	The role of NK cells in oncolytic viral therapy: a focus on hepatocellular carcinoma. 2021 , 5, 304-322		
369	Surveillance for hepatocellular carcinoma in patients with advanced liver fibrosis. 2021 , 27, 64-72		2
368	Therapeutic Decision Making in Hepatocellular Carcinoma According to Age and Child-Pugh Class: A Nationwide Cohort Analysis in South Korea. 2021 , 2021, 6640121		2
367	Type of Necrosis Influences Prognosis in Hepatocellular Carcinoma After the First Transarterial Chemoembolization. 2021 , 27, e929884		1
366	Hepatocellular carcinoma in non-alcoholic fatty liver disease-a review of an emerging challenge facing clinicians. 2021 , 10, 59-75		9
365	Surveillance as Determinant of Long-Term Survival in Non-Transplanted Hepatocellular Carcinoma Patients. 2021 , 13,		4
364	Treatment stage migration and treatment sequences in patients with hepatocellular carcinoma: drawbacks and opportunities. 2021 , 147, 2471-2481		3
363	Comparison of the Phytochemical Properties, Antioxidant Activity and Cytotoxic Effect on HepG2 Cells in Mongolian and Taiwanese Rhubarb Species. 2021 , 26,		2
362	Albumin-bilirubin index and platelet-albumin-bilirubin index contribute to identifying survival benefit candidates in patients with hepatocellular carcinoma and Child-Pugh grade A undergoing transcatheter arterial chemoembolization with sorafenib treatment. 2021 , 9, 237		0
361	Hepatic Arterial Infusion Chemotherapy with Modified FOLFOX as an Alternative Treatment Option in Advanced Hepatocellular Carcinoma Patients with Failed or Unsuitability for Transarterial Chemoembolization. 2021 , 28 Suppl 1, S157-S166		2
360	A Pre-Operative Prognostic Score for Patients With Advanced Hepatocellular Carcinoma Who Underwent Resection. 2021 , 11, 569515		
359	Case Report: Transarterial Chemoembolization in Combination With Tislelizumab Downstages Unresectable Hepatocellular Carcinoma Followed by Radical Salvage Resection. 2021 , 11, 667555		4
358	Epidemiological projections of viral-induced hepatocellular carcinoma in the perspective of WHO global hepatitis elimination. <i>Liver International</i> , 2021 , 41, 915-927	7.9	7
357	Are radiological endpoints surrogate outcomes of overall survival in hepatocellular carcinoma treated with transarterial chemoembolization?. <i>Liver International</i> , 2021 , 41, 1105-1116	7.9	3
356	Lack of Response to Transarterial Chemoembolization for Intermediate-Stage Hepatocellular Carcinoma: Abandon or Repeat?. 2021 , 298, 680-692		6

355	Downstaging and Resection of Initially Unresectable Hepatocellular Carcinoma with Tyrosine Kinase Inhibitor and Anti-PD-1 Antibody Combinations. 2021 , 10, 320-329	13
354	Changing trends in hepatocellular carcinoma management: Results from a nationwide database in the last decade. 2021 , 146, 48-55	2
353	Identifying SLC27A5 as a potential prognostic marker of hepatocellular carcinoma by weighted gene co-expression network analysis and in vitro assays. 2021 , 21, 174	4
352	Comparison of Efficacy of Systemic Therapies in Advanced Hepatocellular Carcinoma: Updated Systematic Review and Frequentist Network Meta-Analysis of Randomized Controlled Trials. 2021 , 8, 145-154	6
351	Radiomics Model Based on Gadoxetic Acid Disodium-Enhanced MR Imaging to Predict Hepatocellular Carcinoma Recurrence After Curative Ablation. 2021 , 13, 2785-2796	0
350	Prognosis of hepatocellular carcinoma metastasizing to the oral cavity. 2021 , 43, 9	0
349	Organ specific responses to first-line lenvatinib plus anti-PD-1 antibodies in patients with unresectable hepatocellular carcinoma: a retrospective analysis. 2021 , 9, 19	10
348	Development of TACE Refractoriness Scores in Hepatocellular Carcinoma. 2021 , 8, 615133	1
347	Quantitative assessment of HCC wash-out on CT is a predictor of early complete response to TACE. 2021 , 31, 6578-6588	4
346	The effect of Telomere Lengthening on Genetic Diseases. 2021 , 11, 254-261	
345	Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib for Patients With Unresectable or Metastatic Hepatocellular Carcinoma. 2021 , 4, e214846	16
344	Re-evaluating Transarterial Chemoembolization Failure/Refractoriness: A Survey by Chinese College of Interventionalists. 2021 , 9, 521-527	3
343	Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression. 2021 , 125, 190-199	6
342	Locoregional Combined With Systemic Therapies for Advanced Hepatocellular Carcinoma: An Inevitable Trend of Rapid Development. 2021 , 8, 635243	4
341	Duration of response after DEB-TACE compared to lipiodol-TACE in HCC-naïve patients: a propensity score matching analysis. 2021 , 31, 7512-7522	3
340	Integrated profiling identifies ITGB3BP as prognostic biomarker for hepatocellular carcinoma. 2021 , 21, 712-723	
339	Combination therapy for advanced hepatocellular carcinoma: do we see the light at the end of the tunnel?. 2021 , 10, 180-192	11
338	Comparison of HBV reactivation between patients with high HBV-DNA and low HBV-DNA loads undergoing PD-1 inhibitor and concurrent antiviral prophylaxis. 2021 , 70, 3207-3216	3

337	Chinese expert consensus on technical recommendations for the standard operation of drug-eluting beads for transvascular embolization. 2021 , 9, 714	5
336	Regulatory mechanisms and therapeutic targeting of vasculogenic mimicry in hepatocellular carcinoma. 2021 , 166, 105507	5
335	Understanding surrogate measures of overall survival after trans-arterial chemoembolization of hepatocellular carcinoma. <i>Liver International</i> , 2021 , 41, 891-893	7.9 0
334	Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: A Subgroup Analysis of Asian Patients in the Phase 3 KEYNOTE-240 Trial. 2021 , 10, 275-284	9
333	Machine-learning analysis of contrast-enhanced computed tomography radiomics predicts patients with hepatocellular carcinoma who are unsuitable for initial transarterial chemoembolization monotherapy: A multicenter study. 2021 , 14, 101034	6
332	Cytokines regulators as potential diagnostic and therapeutic biomarkers for human hepatocellular carcinoma. 2021 , 246, 1343-1354	0
331	Effect of antiviral therapy in patients with low HBV DNA level on transarterial chemoembolization for hepatocellular carcinoma. 2021 , 28, 1011-1018	0
330	Hepatic Resection for Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. 2021 , 2, e065	2
329	Prognostic Model for the Risk Stratification of Early and Late Recurrence in Hepatitis B Virus-Related Small Hepatocellular Carcinoma Patients with Global Histone Modifications. 2021 , 8, 493-505	0
328	Predictive impact of prognostic nutritional index in early-stage hepatocellular carcinoma after operative microwave ablation. 2021 , 45, 202-202	0
327	Impact of COVID-19 Pandemic on Intervals and Outcomes of Repeated Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma. 2021 , 11, 602700	0
326	Lenvatinib Plus Camrelizumab versus Lenvatinib Monotherapy as Post-Progression Treatment for Advanced Hepatocellular Carcinoma: A Short-Term Prognostic Study. 2021 , 13, 4233-4240	3
325	Effects of transarterial chemoembolization on the immunological function of patients with hepatocellular carcinoma. 2021 , 22, 554	9
324	Random Survival Forests to Predict Disease Control for Hepatocellular Carcinoma Treated With Transarterial Chemoembolization Combined With Sorafenib. 2021 , 8, 618050	5
323	Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Predictors of Outcomes in Patients With Unresectable Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization Plus Sorafenib. 2021 , 8, 624366	2
322	The therapeutic landscape of hepatocellular carcinoma.. 2021 , 2, 505-552	3
321	The impact of portal vein tumor thrombosis on survival in patients with hepatocellular carcinoma treated with different therapies: A cohort study. 2021 , 16, e0249426	5
320	Quantitative dual-energy CT for evaluating hepatocellular carcinoma after transarterial chemoembolization. 2021 , 11, 11127	0

319	Liver resection for hepatocellular carcinoma larger than 10 cm: A multi-institution long-term observational study. 2021 , 13, 476-492		1
318	Selection of first-line systemic therapies for advanced hepatocellular carcinoma: A network meta-analysis of randomized controlled trials. 2021 , 27, 2415-2433		7
317	The clinical, prognostic and therapeutic significance of liver cancer stem cells and their markers. 2021 , 45, 101664		3
316	Three-day postoperative antibiotics reduces post-hepatectomy infection rate in hepatitis B virus-related hepatocellular carcinoma. 2021 , 36, 2531-2539		1
315	Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma: Radiologic and Clinical Factors Predictive of Survival. 2021 , 216, 1566-1573		3
314	Clinical Outcomes of Ablation Compared with Resection for Single Hepatocellular Carcinoma Lesions, as a Primary Treatment or Bridging to Liver Transplantation: A Retrospective Comparative Study. 2021 , 26, e931980		0
313	Downregulation of snoRNA SNORA52 and Its Clinical Significance in Hepatocellular Carcinoma. 2021 , 2021, 7020637		1
312	Clinical impact of sexual dimorphism in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). <i>Liver International</i> , 2021 , 41, 1713-1733	7.9	13
311	p53 Mutation at Serine 249 and Its Gain of Function Are Highly Related to Hepatocellular Carcinoma after Smoking Exposure. 2021 , 24, 171-181		3
310	The multidisciplinary management of hepatocellular carcinoma with portal vein tumor thrombus. 2021 , 15, 148-154		2
309	Effectiveness of Transarterial Chemoembolization-First Treatment for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis. 2021 , 8, 587-598		
308	Analysis of Medical Use and Treatment Costs of Hepatocellular Carcinoma Patients Using National Patient Sample Data. 2021 , 31, 153-159		
307	Adjuvant versus Neoadjuvant Immunotherapy for Hepatocellular Carcinoma: Clinical and Immunologic Perspectives. 2021 , 41, 263-276		4
306	Donafenib treatment for hepatocellular carcinoma: A case report. 2021 , 100, e26373		1
305	Microvascular invasion may be the determining factor in selecting TACE as the initial treatment in patients with hepatocellular carcinoma. 2021 , 100, e26584		
304	Hepatic Arterial Infusion Chemotherapy Is a Feasible Treatment Option for Hepatocellular Carcinoma: A New Update. 2021 , 8, 145-152		1
303	Neoadjuvant Cabozantinib and Nivolumab Converts Locally Advanced HCC into Resectable Disease with Enhanced Antitumor Immunity. 2021 , 2, 891-903		18
302	A new discovery of STAT4 single nucleotide polymorphisms associated with hepatocellular carcinoma risk in Chinese Han population: a case-control study. 2021 , 41,		

301	PD-1 Blockade for Hepatocellular Carcinoma: Current Research and Future Prospects. 2021 , 8, 887-897	3
300	Role of Virus-Related Chronic Inflammation and Mechanisms of Cancer Immune-Suppression in Pathogenesis and Progression of Hepatocellular Carcinoma. 2021 , 13,	4
299	Comparison of 10 noninvasive models for predicting overall survival in patients with intermediate-stage hepatocellular carcinoma. 2021 , 100, e27000	0
298	Sorafenib Versus Apatinib Both Combined Transarterial Chemoembolization for Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis: A Comparative Retrospective Study. 2021 , 11, 673378	7
297	Atezolizumab plus bevacizumab for unresectable or metastatic hepatocellular carcinoma. 2021 , 21, 927-939	1
296	Magnetic mesoporous embolic microspheres in transcatheter arterial chemoembolization for liver cancer. 2021 , 130, 374-384	2
295	International Validation of the SORG Machine-learning Algorithm for Predicting the Survival of Patients with Extremity Metastases Undergoing Surgical Treatment. 2021 ,	2
294	Hepatic Artery Infusion Chemotherapy Using Fluorouracil, Leucovorin, and Oxaliplatin versus Transarterial Chemoembolization as Initial Treatment for Locally Advanced Hepatocellular Carcinoma: A Propensity Score-Matching Analysis. 2021 , 32, 1267-1276.e1	6
293	Changes in treatment pattern and costs in advanced hepatocellular carcinoma (HCC). 2021 , 1-8	
292	Preparation of Near-Infrared/Photoacoustic Dual-Mode Imaging and Photothermal/Chemo Synergistic Theranostic Nanoparticles and Their Imaging and Treating of Hepatic Carcinoma. 2021 , 11, 750807	2
291	Current and Emerging Tools for Hepatocellular Carcinoma Surveillance. 2021 , 5, 1972-1986	4
290	Gas generating microspheres for immediate release of Hsp90 inhibitor aiming at postembolization hypoxia in transarterial chemoembolization therapy of hepatocellular carcinoma. 2021 , 607, 120988	1
289	Biomarkers and Future Perspectives for Hepatocellular Carcinoma Immunotherapy. 2021 , 11, 716844	4
288	Salvage External Beam Radiotherapy after Incomplete Transarterial Chemoembolization for Hepatocellular Carcinoma: A Meta-Analysis and Systematic Review. 2021 , 57,	0
287	Hepatitis B virus x gene-downregulated growth-arrest specific 5 inhibits the cell viability and invasion of hepatocellular carcinoma cell lines by activating Y-box-binding protein 1/p21 signaling. 2021 , 1	0
286	Hepatocellular carcinoma in a non-cirrhotic liver with a tumor thrombus. 2021 , 9, e04800	
285	Dysregulation of Non-coding RNAs mediates Cisplatin Resistance in Hepatocellular Carcinoma and therapeutic strategies. 2021 , 176, 105906	0
284	Increased Liquefactive Necrosis Formation After Transarterial Chemoembolization Combined with Molecular Targeted Agents Plus Immune Checkpoint Inhibitors for Hepatocellular Carcinoma. 2021 , 13, 6935-6941	2

283	Anatomic versus non-anatomic resection of hepatocellular carcinoma with microvascular invasion: A systematic review and meta-analysis. 2021 , 44, 1143-1150	7
282	Locoregional therapy patterns and healthcare economic burden of patients with hepatocellular carcinoma in the USA. 2021 , 8, HEP37	
281	Viral Status and Efficacy of Immunotherapy in Hepatocellular Carcinoma: A Systematic Review With Meta-Analysis. 2021 , 12, 733530	5
280	Combination of transcatheter arterial chemoembolization and portal vein embolization for patients with hepatocellular carcinoma: a review. 2021 , 19, 293	2
279	Lipiodol as an intra-procedural imaging biomarker for liver tumor response to transarterial chemoembolization: Post-hoc analysis of a prospective clinical trial. 2021 , 78, 194-200	1
278	Clinical practice of transarterial chemoembolization for hepatocellular carcinoma: consensus statement from an international expert panel of International Society of Multidisciplinary Interventional Oncology (ISMIO). 2021 , 10, 661-671	4
277	Prospective Multi-Center Korean Registry of Transcatheter Arterial Chemoembolization with Drug-Eluting Embolics for Nodular Hepatocellular Carcinoma: A Two-Year Outcome Analysis. 2021 , 22, 1658-1670	2
276	Radiomics Signature: A potential biomarker for the prediction of survival in Advanced Hepatocellular Carcinoma. 2021 , 18, 2276-2284	4
275	Evaluating the predictive power of circulating tumor cells for the prognosis of transarterial chemoembolization treatment on patients with advanced hepatocellular carcinoma. 2021 , 100, e24060	1
274	Characteristics and etiologies of hepatocellular carcinoma in patients without cirrhosis: When East meets West. 2021 , 16, e0244939	3
273	Emerging Trends in the Treatment of Advanced Hepatocellular Carcinoma: A Radiological Perspective. 2021 , 22, 1822-1833	2
272	Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma. 2021 , 18, 293-313	80
271	Ramucirumab for Patients with Intermediate-Stage Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Results from Two Phase 3 Studies (REACH and REACH-2). 2021 , 10, 451-460	3
270	Balloon-Occluded Transarterial Chemoembolization: In Which Size Range Does It Perform Best? A Comparison of Its Efficacy versus Conventional Transarterial Chemoembolization, Using Propensity Score Matching. 2021 , 10, 522-534	1
269	Single-center randomized trial comparing conventional chemoembolization versus doxorubicin-loaded polyethylene glycol microspheres for early- and intermediate-stage hepatocellular carcinoma. 2021 , 30, 258-266	1
268	Regorafenib in previously treated advanced hepatocellular carcinoma: Impact of prior immunotherapy and adverse events. <i>Liver International</i> , 2020 , 40, 2263-2271	7.9 15
267	Development and Validation of a Novel Immune-Gene Pairs Prognostic Model Associated with CTNNB1 Alteration in Hepatocellular Carcinoma. 2020 , 26, e925494	8
266	Treatment patterns and survival in hepatocellular carcinoma in the United States and Taiwan. 2020 , 15, e0240542	5

265	Growth hormone upregulates the pro-tumorigenic galectin 1 in mouse liver. 2019 , 8, 1108-1117	4
264	Comparison of the prognostic value of platelet-based prognostic models in patients with malignant hepatic tumors after TACE therapy. 2019 , 34, e201900710	2
263	Hepatocellular Carcinoma in Korea Between 2008 and 2011: an Analysis of Korean Nationwide Cancer Registry. 2020 , 20, 41-52	8
262	Interferon alpha antagonizes the anti-hepatoma activity of the oncolytic virus M1 by stimulating anti-viral immunity. 2017 , 8, 24694-24705	9
261	An autophagy-related gene expression signature for survival prediction in multiple cohorts of hepatocellular carcinoma patients. 2018 , 9, 17368-17395	16
260	Laser ablation is superior to TACE in large-sized hepatocellular carcinoma: a pilot case-control study. 2018 , 9, 17483-17490	5
259	Arenobufagin intercalates with DNA leading to G2 cell cycle arrest via ATM/ATR pathway. 2015 , 6, 34258-75	32
258	Matrix stiffness-mediated effects on stemness characteristics occurring in HCC cells. 2016 , 7, 32221-31	49
257	Cancer burden and trends in China: A review and comparison with Japan and South Korea. 2020 , 32, 129-139	45
256	Classification and Current Treatment of Hepatocellular Carcinoma. 2, 8	2
255	2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. 2019 , 20, 1042-1113	96
254	The role of scheduled second TACE in early-stage hepatocellular carcinoma with complete response to initial TACE. 2017 , 23, 42-50	8
253	Switching to systemic therapy after locoregional treatment failure: Definition and best timing. 2020 , 26, 155-162	21
252	Diagnosis of hepatocellular carcinoma: Which MRI contrast agent? Which diagnostic criteria?. 2020 , 26, 309-311	3
251	Liver transplantation for hepatocellular carcinoma - factors influencing outcome and disease-free survival. 2015 , 21, 12071-82	12
250	Barcelona clinic liver cancer nomogram and others staging/scoring systems in a French hepatocellular carcinoma cohort. 2017 , 23, 2545-2555	20
249	Prediction of early-stage hepatocellular carcinoma using OncoScan chromosomal copy number aberration data. 2017 , 23, 7818-7829	6
248	Nonalcoholic fatty liver disease and liver transplantation - Where do we stand?. 2018 , 24, 1491-1506	66

247	Hepatocellular carcinoma in Latin America: Diagnosis and treatment challenges. 2018 , 24, 4224-4229	12
246	Intermediate-advanced hepatocellular carcinoma in Argentina: Treatment and survival analysis. 2019 , 25, 3607-3618	10
245	Identification of hepatitis B virus and liver cancer bridge molecules based on functional module network. 2019 , 25, 4921-4932	2
244	Validation of the six-and-twelve criteria among patients with hepatocellular carcinoma and performance score 1 receiving transarterial chemoembolization. 2020 , 26, 1805-1819	2
243	Validation and evaluation of clinical prediction systems for first and repeated transarterial chemoembolization in unresectable hepatocellular carcinoma: A Chinese multicenter retrospective study. 2020 , 26, 657-669	4
242	A New Cell Block Method for Multiple Immunohistochemical Analysis of Circulating Tumor Cells in Patients with Liver Cancer. 2016 , 48, 1229-1242	11
241	Sub-classification of Advanced-Stage Hepatocellular Carcinoma: A Cohort Study Including 612 Patients Treated with Sorafenib. 2018 , 50, 366-373	8
240	Hepatocellular carcinoma in Micronesians, a growing Pacific Islander population in the U.S. 2018 , 8,	4
239	Biomarkers for hepatocellular cancer. 2020 , 12, 558-573	13
238	Usefulness of the MESH score in a European hepatocellular carcinoma cohort. 2017 , 9, 711-714	4
237	Can More Aggressive Treatment Improve Prognosis in Patients with Hepatocellular Carcinoma? A Direct Comparison of the Hong Kong Liver Cancer and Barcelona Clinic Liver Cancer Algorithms. 2018 , 12, 94-101	11
236	2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. 2019 , 13, 227-299	151
235	Uvangoletin, extracted from <i>Sarcandra glabra</i> , exerts anticancer activity by inducing autophagy and apoptosis and inhibiting invasion and migration on hepatocellular carcinoma cells. 2022 , 94, 153793	0
234	In the Era of Systemic Therapy for Hepatocellular Carcinoma Is Transarterial Chemoembolization Still a Card to Play?. 2021 , 13,	0
233	Application of artificial intelligence in liver diseases: From diagnosis to treatment. 2021 , 2, 133-140	
232	Direct-acting antivirals reduce the risk of tumour progression of hepatocellular carcinoma after curative treatment. 2021 ,	0
231	Current epidemiology in hepatocellular carcinoma. 2021 , 15, 1295-1307	15
230	Sorafenib Combined with Chemoembolization for Locally Advanced Hepatocellular Carcinoma with Macroscopic Vascular Invasion: A Propensity Score Analysis. 2021 , 11,	1

- 229 MRI-based Nomogram Predicts the Risk of Progression of Unresectable Hepatocellular Carcinoma After Combined Lenvatinib and anti-PD-1 Antibody Therapy. **2021**, 0
- 228 Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Transarterial Chemoembolization for Large Hepatocellular Carcinoma: A Randomized Phase III Trial. **2021**, JCO2100608 15
- 227 Clinical outcomes of patients with two small hepatocellular carcinomas. **2021**, 13, 1439-1449
- 226 Lenvatinib Combined with Anti-PD-1 Antibodies Plus Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study. **2021**, 8, 1233-1240 3
- 225 Cytokine-Induced Killer Cells for the Adjuvant Treatment of Patients with HCC. **2017**, 69-84
- 224 Management of hepatocellular carcinoma: a study on 240 patients in a single referral center. **2018**, 50, 19
- 223 Anti-angiogenics in Hepatocellular Cancer Therapy. **2019**, 435-446
- 222 Analysis of Existing Guidelines and Randomized, Controlled, Clinical Trials for Development of [Guideline of Clinical Trial on Herbal Medicinal Product for Liver Cancer]. **2019**, 40, 89-116
- 221 Conventional Chemoembolization for Hepatocellular Carcinoma: Role of Cone-Beam Computed Tomography Guidance. **2019**, 19, 19-29 0
- 220 Tenofovir and Entecavir Have Similar Renal Adverse Events on Hepatocellular Carcinoma Patients Treated with Transarterial Chemoembolization. **2019**, 19, 128-135 1
- 219 Regional Therapies in Hepatocellular Carcinoma and Cholangiocarcinoma. **2020**, 311-322
- 218 Development and validation of a risk score for predicting mortality after resection of primary hepatocellular carcinoma. **2020**, 12, 11878-11892
- 217 Modern principles of hepatocellular carcinoma treatment. **2020**, 25, 15-26
- 216 Added Value of CT Arterial Subtraction Images in Liver Imaging Reporting and Data System Treatment Response Categorization for Transcatheter Arterial Chemoembolization-Treated Hepatocellular Carcinoma. **2021**, 56, 109-116 1
- 215 Role of residual liver volumetry and function in prediction of liver tolerability after transarterial chemoembolization for hepatocellular carcinoma in cirrhotic patients: deriving a clinical decision support score. **2020**, 51,
- 214 Clinical efficacy of external beam radiotherapy complementing incomplete transarterial chemoembolization for hepatocellular carcinoma.
- 213 Current role of systemic therapy in transarterial chemotherapy refractory hepatocellular carcinoma patients. **2021**, 10, 183-188
- 212 The role of muscle depletion and visceral adiposity in HCC patients aged 65 and over undergoing TACE. **2021**, 21, 1164 1

211	Therapy of Intermediate-Stage Hepatocellular Carcinoma: Current Evidence and Clinical Practice. 2020 , 37, 456-465	3
210	Treatment Options for Early-Stage Hepatocellular Carcinoma. 2020 , 37, 448-455	
209	Ambulatory end-stage liver disease in Ghana; patient profile and utility of alpha fetoprotein and aspartate aminotransferase: platelet ratio index. 2020 , 20, 428	2
208	Hepatocellular Carcinoma (HCC), Where do we stand? Current situation. 2020 , 36, 344-348	3
207	Proposal and Validation of a Novel Scoring System for Hepatocellular Carcinomas Beyond Curability Borders. 2021 ,	0
206	Transarterial chemoembolization with hepatic arterial infusion chemotherapy plus S-1 for hepatocellular carcinoma. 2020 , 26, 3975-3988	1
205	Transarterial chemoembolization with hepatic arterial infusion chemotherapy plus S-1 for hepatocellular carcinoma. 2020 , 26, 3971-3984	
204	Caracterizaci3n, manejo y pron3stico de una cohorte de pacientes cirr3gicos con carcinoma hepatocelular. Hospital Pablo Tob3 Uribe 2012-2018. 2020 , 134-144	0
203	Selective internal radiation therapies for unresectable early-, intermediate- or advanced-stage hepatocellular carcinoma: systematic review, network meta-analysis and economic evaluation. 2020 , 24, 1-264	2
202	Imaging Modalities for Hepatocellular Carcinoma Surveillance: Expanding Horizons beyond Ultrasound. 2020 , 20, 99-105	0
201	Surgery versus external beam radiotherapy for hepatocellular carcinoma involving the inferior vena cava or right atrium: A systematic review and meta-analysis.	
200	Predictive scores for hepatocellular carcinoma: a race with no winners?. 2020 , 8, 1211	
199	Assessment of liver cancer biomarkers. 2020 , 13, S29-S39	3
198	Inhibition of mu-opioid receptor suppresses proliferation of hepatocellular carcinoma cells via CD147-p53-MAPK cascade signaling pathway. 2021 , 13, 3967-3986	1
197	Consensus on the secondary prevention of primary liver cancer. 2021 , 15, 1289-1300	1
196	Downstaging Conversion Therapy in Patients With Initially Unresectable Advanced Hepatocellular Carcinoma: An Overview. 2021 , 11, 772195	1
195	Hepatocellular Carcinoma in Non-Alcoholic Fatty Liver Disease: From Epidemiology to Diagnostic Approach. 2021 , 13,	5
194	Case Report: Hepatic Artery Infusion Chemotherapy After Stage I ALPPS in a Patient With Huge HCC.. 2021 , 8, 746618	0

- 193 Supervised learning based on tumor imaging and biopsy transcriptomics predicts response of hepatocellular carcinoma to transarterial chemoembolization. **2021**, 2, 100444
- 192 Multimarker Panels for Detection of Early Stage Hepatocellular Carcinoma: A Prospective, Multicenter, Case-Control Study. **2021**, 6
- 191 Identification of the Immune Cell Infiltration Landscape in Hepatocellular Carcinoma to Predict Prognosis and Guide Immunotherapy.. **2021**, 12, 777931 2
- 190 Non-alcoholic steatohepatitis and risk of hepatocellular carcinoma. **2021**, 2
- 189 The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality. **2021**, 12
- 188 Cost-Effectiveness of Adjuvant Immunotherapy With Cytokine-Induced Killer Cell for Hepatocellular Carcinoma Based on a Randomized Controlled Trial and Real-World Data.. **2021**, 11, 728740 0
- 187 Clinical Research Progress of Apatinib in the Treatment of Hepatocellular Carcinoma. **2021**, 11, 6195-6200
- 186 Predictive scores for hepatocellular carcinoma: a race with no winners?. **2020**, 8, 1211-1211
- 185 Predictive factors for long-term survival in patients with advanced hepatocellular carcinoma treated with sorafenib. **2020**, 33, 1
- 184 Transcatheter chemoembolization plus percutaneous radiofrequency ablation versus laparoscopic radiofrequency ablation: improved outcome for inoperable hepatocellular carcinoma. **2021**, 38, 1685-1694 0
- 183 Tenofovir vs. entecavir on recurrence of hepatitis B virus-related hepatocellular carcinoma beyond Milan criteria after hepatectomy.. **2021**, 135, 0
- 182 Cabozantinib plus atezolizumab for the treatment of advanced hepatocellular carcinoma: Shedding light on the preclinical rationale and clinical trials.. **2022**, 0
- 181 Treatment and the prognosis of hepatocellular carcinoma in Asia. *Liver International*, **2021**, 7.9 3
- 180 Transarterial Chemoembolization for Hepatocellular Carcinoma in Clinical Practice: Temporal Trends and Survival Outcomes of an Iterative Treatment.. **2022**, 12, 822507 0
- 179 Subsequent Treatment after Transarterial Chemoembolization Failure/Refractoriness: A Review Based on Published Evidence. **2022**, 000, 000-000 0
- 178 The therapeutic potential of exosomes derived from different cell sources in liver diseases.. **2022**, 0
- 177 mPEG-Cholic acid/TPGS mixed micelles for combined delivery of paclitaxel and bufalin to treat hepatocellular carcinoma.. **2022**, 1-31 1
- 176 The role of postoperative radiotherapy in hepatocellular carcinoma.. **2022**, 11, 123-125

175	Multi-Task Deep Learning Approach for Simultaneous Objective Response Prediction and Tumor Segmentation in HCC Patients with Transarterial Chemoembolization.. 2022 , 12,	0
174	The past, present and future of conversion therapy for liver cancer. 2021 , 11, 4711-4724	0
173	The Role of Hepatic Arterial Infusion Chemotherapy in the Combination Therapy of Advanced Hepatocellular Carcinoma. 2022 , 12, 1881-1887	
172	Dynamic Nomogram for Predicting Macrovascular Invasion of Patients with Unresectable Hepatocellular Carcinoma after Transarterial Chemoembolization.. 2022 , 13, 1914-1922	
171	Countdown on Hepatitis B Elimination by 2030: The Global Burden of Liver Disease Related to Hepatitis B and Association With Socioeconomic Status.	
170	Stereotactic body radiation therapy as a salvage treatment for single viable hepatocellular carcinoma at the site of incomplete transarterial chemoembolization: a retrospective analysis of 302 patients.. 2022 , 22, 175	1
169	Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Unresectable Hepatocellular Carcinoma: Efficacy and Systemic Immune Response.. 2022 , 13, 847601	1
168	The Prevalence and the Impact of Frailty in Hepato-Biliary Pancreatic Cancers: A Systematic Review and Meta-Analysis.. 2022 , 11,	2
167	Nomograms for Predicting Hepatocellular Carcinoma Recurrence and Overall Postoperative Patient Survival.. 2022 , 12, 843589	2
166	Anti-Cancer Activity of Venom on Hepatocellular Carcinoma in 3D Cell Culture.. 2022 , 27,	
165	Progression-Free Survival of a Patient with Advanced Hepatocellular Carcinoma Treated with Adoptive Cell Therapy Using Natural Killer Cells: A Case Report.. 2022 , 15, 255-266	
164	Deep learning for evaluation of microvascular invasion in hepatocellular carcinoma from tumor areas of histology images.. 2022 , 1	0
163	Real-life data on the impact of successful downstaging in patients with hepatocellular carcinoma: A Dutch Multicenter Study.. 2021 ,	0
162	Yttrium-90 radioembolization for unresectable hepatocellular carcinoma: predictive modeling strategies to anticipate tumor response and improve patient selection.. 2022 , 1	0
161	Prognostic Comparison Between Liver Resection and Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma Patients With Bile Duct Tumor Thrombus: A Propensity-Score Matching Analysis.. 2022 , 12, 835559	0
160	Chinese expert consensus on conversion therapy for hepatocellular carcinoma (2021 edition).. 2022 , 11, 227-252	0
159	Development and Validation of a Prediction Model for Predicting the Prognosis of Postoperative Patients with Hepatocellular Carcinoma.. 2022 , 15, 3625-3637	0
158	Optimal time point of response assessment for predicting survival is associated with tumor burden in hepatocellular carcinoma receiving repeated transarterial chemoembolization.. 2022 , 1	0

157	TwinLiverNet: Predicting TACE Treatment Outcome from CT scans for Hepatocellular Carcinoma using Deep Capsule Networks. 2021 , 2021, 3039-3043	1
156	ANTXR1 as a potential prognostic biomarker for hepatitis B virus-related hepatocellular carcinoma identified by a weighted gene correlation network analysis.. 2021 , 12, 3079-3092	1
155	Development of a Prognostic Nomogram in Hepatocellular Carcinoma with Portal Vein Tumor Thrombus Following Trans-Arterial Chemoembolization with Drug-Eluting Beads.. 2021 , 13, 9367-9377	1
154	Is There Still a Place for Tyrosine Kinase Inhibitors for the Treatment of Hepatocellular Carcinoma at the Time of Immunotherapies? A Focus on Lenvatinib.. 2021 , 13,	0
153	Liver MRI and clinical findings to predict response after drug eluting bead transarterial chemoembolization in hepatocellular carcinoma.. 2021 , 11, 24076	2
152	Yttrium-90 Radioembolization Is Associated with Better Clinical Outcomes in Patients with Hepatocellular Carcinoma Compared with Conventional Chemoembolization: A Propensity Score-Matched Study.. 2021 , 8, 1565-1577	1
151	Hepatic arterial infusion of oxaliplatin plus raltitrexed in unresectable hepatocellular carcinoma with or without portal vein tumour thrombosis.. 2022 , 10, goac016	0
150	Pembrolizumab monotherapy for previously untreated advanced hepatocellular carcinoma: data from the open-label, phase 2 KEYNOTE-224 trial.. 2022 ,	2
149	Immune Checkpoint Inhibitors as Therapy to Down-Stage Hepatocellular Carcinoma Prior to Liver Transplantation.. 2022 , 14,	2
148	Efficacy and Safety of TACE Combined With Lenvatinib Plus PD-1 Inhibitors Compared With TACE Alone for Unresectable Hepatocellular Carcinoma Patients: A Prospective Cohort Study.. 2022 , 12, 874473	0
147	Optimization of the BCLC Staging System for Locoregional Therapy for Hepatocellular Carcinoma by Using Quantitative Tumor Burden Imaging Biomarkers at MRI.. 2022 , 212426	1
146	Table_1.DOCX. 2020 ,	
145	Data_Sheet_1.DOCX. 2020 ,	
144	Table_1.docx. 2020 ,	
143	Long-Term Trends in Incidence, Mortality and Disease Burden of Liver Cancer Due to Specific Etiologies in Hubei Province, 1990-2019.	
142	Case Report: Massive Hepatocellular Carcinoma Complete Surgical Resection After Portal Vein Embolization and Multimodality Therapy. 2022 , 2,	
141	Digestive cancer screening across Europe.. 2022 ,	1
140	Non-Apoptotic Programmed Cell Death-Related Gene Signature Correlates With Stemness and Immune Status and Predicts the Responsiveness of Transarterial Chemoembolization in Hepatocellular Carcinoma.. 2022 , 10, 844013	

139	Expert consensus on the role of hematological markers in the early clinical screening of hepatocellular carcinoma. 2022,	0
138	The Safety Profile of Hepatectomy Following Preoperative Systemic Therapy with Lenvatinib Plus Anti-PD-1 Antibodies Versus Hepatectomy Alone in Patients With Hepatocellular Carcinoma. 2022, 3, e163	0
137	The efficacy of anatomic resection for hepatocellular carcinoma within Milan criteria: A retrospective single-institution case-matched study. 2022,	1
136	Cost-effectiveness analysis of donafenib versus lenvatinib for first-line treatment of unresectable or metastatic hepatocellular carcinoma.. 2022,	0
135	Impact of Extended Use of Ablation Techniques in Cirrhotic Patients with Hepatocellular Carcinoma: A Cost-Effectiveness Analysis. 2022, 14, 2634	
134	Trial Designs for Integrating Novel Therapeutics into the Management of Intermediate-Stage Hepatocellular Carcinoma. Volume 9, 517-536	
133	Pretreatment Metabolic Parameters Measured by 18F-FDG PET to Predict the Pathological Treatment Response of HCC Patients Treated With PD-1 Inhibitors and Lenvatinib as a Conversion Therapy in BCLC Stage C. 12,	0
132	Hepatocellular Carcinoma Due to Nonalcoholic Fatty Liver Disease: Current Concepts and Future Challenges. Volume 9, 477-496	1
131	Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma.	12
130	The combination treatment strategy of lenvatinib for hepatocellular carcinoma: a real-world study.	1
129	AdipoR1 Regulates Ionizing Radiation-Induced Ferroptosis in HCC cells through Nrf2/xCT Pathway. 2022, 2022, 1-14	0
128	Preoperative and postoperative nomograms for predicting early recurrence of hepatocellular carcinoma without macrovascular invasion after curative resection. 2022, 22,	0
127	Second-line treatment of advanced hepatocellular carcinoma: Time for more individualized treatment options?. 2022, 14, 1074-1086	
126	Laparoscopic versus open liver resection for resectable HCC with BCLC stage B: a propensity score-matched analysis.	0
125	Transarterial chemoembolization failure/refractoriness: A scientific concept or pseudo-proposition. 2022, 14, 528-537	
124	Population Pharmacokinetic Modeling of Lenvatinib in Chinese Patients with Advanced Hepatocellular Carcinoma using Real-World Data.	
123	TACE with dicycloplatin in patients with unresectable hepatocellular carcinoma: a multicenter randomized phase II trial.	0
122	Embolization therapy with microspheres for the treatment of liver cancer: State-of-the-art of clinical translation. 2022,	3

- 121 Ranking of transarterial and targeted therapies for advanced hepatocellular carcinoma in the era of immuno-oncology: A network meta-analysis of randomized sorafenib-controlled trials.
- 120 Correlation of molecular alterations with pathological features in hepatocellular carcinoma: Literature review and experience of an Italian center. **2022**, 28, 2854-2866
- 119 Summary of key guidelines for locoregional treatment of HCC in Asia, Europe, South and North America. 1
- 118 A novel lncRNA RP11-386G11.10 reprograms lipid metabolism to promote hepatocellular carcinoma progression. **2022**, 63, 101540 0
- 117 Effects of Early TACE Refractoriness on Survival in Patients with Hepatocellular Carcinoma: A Real-World Study. Volume 9, 621-631
- 116 Hepatic arterial infusion oxaliplatin plus raltitrexed and chemoembolization in hepatocellular carcinoma with portal vein invasion: A propensity score-matching cohort study.
- 115 Nivolumab Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma: A Cost-Effectiveness Analysis. 13, 0
- 114 Role of interventional oncology in hepatocellular carcinoma: Future best practice beyond current guidelines. 2
- 113 Arterial enhancement fraction in evaluating the therapeutic effect and survival for hepatocellular carcinoma patients treated with DEB-TACE. **2022**, 22, 0
- 112 Combination approaches in hepatocellular carcinoma: How systemic treatment can benefit candidates to locoregional modalities. **2022**, 28, 3573-3585
- 111 Polymeric nanoparticles for dual-targeted theranostic gene delivery to hepatocellular carcinoma. **2022**, 8, 2
- 110 Comparison of Arterial Infusion Chemotherapy and Chemoembolization for Locally Advanced Hepatocellular Carcinoma: a Multicenter Retrospective Study. 0
- 109 GOLM1 depletion modifies cellular sphingolipid metabolism and adversely affects cell growth. **2022**, 100259
- 108 Transarterial Chemoembolization in Hepatocellular Carcinoma: A Binational Japanese-German Study. Volume 9, 695-705
- 107 Metformin administration is associated with enhanced response to transarterial chemoembolization for hepatocellular carcinoma in type 2 diabetes patients. **2022**, 12, 0
- 106 Lenvatinib Combined With Transarterial Chemoembolization as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Phase III, Randomized Clinical Trial (LAUNCH). 3
- 105 Peripheral naïve CD8 + T cells as a predictive biomarker of response to lenvatinib plus an anti-PD-1 antibody in advanced hepatocellular carcinoma: a biomarker study. 0
- 104 Low bone mineral density is a prognostic factor for elderly patients with HCC undergoing TACE: results from a multicenter study.

103	Lenvatinib, toripalimab plus hepatic arterial infusion chemotherapy in patients with high-risk advanced hepatocellular carcinoma: A biomolecular exploratory, phase II trial. 2022 , 174, 68-77	2
102	Atezolizumab plus bevacizumab versus nivolumab as first-line treatment for advanced or unresectable hepatocellular carcinoma: A cost-effectiveness analysis.	0
101	Transarterial Chemoembolization Combined with Apatinib for Treatment of Advanced Hepatocellular Carcinoma: Analysis of Survival and Prognostic Factors.	0
100	Countdown on hepatitis B elimination by 2030: the global burden of liver disease related to hepatitis B and association with socioeconomic status.	0
99	Transarterial chemoembolization combined with metformin improves the prognosis of hepatocellular carcinoma patients with type 2 diabetes. 13,	0
98	High prevalence of chronic viral hepatitis B and C in Minnesota Somalis contributes to rising hepatocellular carcinoma incidence. 2022 , 28, 5217-5229	0
97	Exosome-derived GTF2H2 from Huh7 cells can inhibit endothelial cell viability, migration, tube formation, and permeability. 2022 , 79, 101922	0
96	Polypharmacology in Clinical Applications Anticancer Polypharmacology. 2022 , 73-132	0
95	Perfusion Change of Hepatocellular Carcinoma During Atezolizumab plus Bevacizumab Treatment: A Pilot Study.	0
94	Phytochemical Profiling, In Vitro Biological Activities, and In-Silico Studies of Ficus vasta Forssk.: An Unexplored Plant. 2022 , 11, 1155	1
93	LncRNA THAP9-AS1 highly expressed in tissues of hepatocellular carcinoma and accelerates tumor cell proliferation. 2022 , 102025	0
92	Programmed cell death protein 1 and tyrosine kinase inhibition plus transcatheter arterial chemoembolization of advanced hepatocellular carcinoma.	0
91	Efficacy of Different Treatments for Patients with Advanced Hepatocellular Carcinoma: A System Review and Network Meta-Analysis. 2022 , 7, 58	0
90	Hepatic arterial infusion chemotherapy combined with PD-1 inhibitors and tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: A tertiary medical center experience. 12,	0
89	Hepatocellular carcinoma. 2022 ,	13
88	Conversion therapy for initially unresectable hepatocellular carcinoma using a combination of toripalimab, lenvatinib plus TACE: real-world study. 2022 , 6,	0
87	Comparable Outcomes in Early Hepatocellular Carcinomas Treated with Trans-Arterial Chemoembolization and Radiofrequency Ablation. 2022 , 10, 2361	1
86	Predicting Outcome in Combination Treatment of TACE and Camrelizumab for Advanced Hepatocellular carcinoma: Tumor Hypervascularity and Reactive Cutaneous Capillary Endothelial Proliferation. Volume 16, 3421-3429	0

- 85 Hepatic Arterial Infusion Chemotherapy with Oxaliplatin Plus Raltitrexed as an Alternative Option in Advanced Hepatocellular Carcinoma Patients with Failure of, or Unsuitability for, Transarterial Chemoembolization. **2022**, 58, 1343 0
- 84 Hepatectomy After Conversion Therapy Using Tyrosine Kinase Inhibitors Plus Anti-PD-1 Antibody Therapy for Patients with Unresectable Hepatocellular Carcinoma. 0
- 83 First- and Second-Line Treatments for Patients with Advanced Hepatocellular Carcinoma in China: A Systematic Review. **2022**, 29, 7305-7326 0
- 82 Spontaneous bacterial peritonitis in hepatocellular carcinoma after PD-1 inhibitor therapy: two clinical cases. **2022**, e11248 0
- 81 Proteo-genomic characterization of virus-associated liver cancers reveals potential subtypes and therapeutic targets. **2022**, 13, 0
- 80 Interval dynamics of transplantability for hepatocellular carcinoma after primary curative resection: risk factors for nontransplantable recurrence. **2022**, 0
- 79 2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma. **2022**, 28, 583-705 3
- 78 Modified AlbuminBilirubin Model for Stratifying Survival in Patients with Hepatocellular Carcinoma Receiving Anticancer Therapy. **2022**, 14, 5083 0
- 77 Nanoscale CaO₂ materials for synergistic transarterial chemoembolization in a VX2 orthotopic rabbit liver cancer model. **2022**, 1 0
- 76 Conversion therapy in liver transplantation for hepatocellular carcinoma: What's new in the era of molecular and immune therapy?. **2022**, 0
- 75 Cost-effectiveness of sintilimab plus bevacizumab biosimilar versus sorafenib for unresectable hepatocellular carcinoma. 0
- 74 Current status of transarterial chemoembolization (TACE) agents in hepatocellular carcinoma treatment. **2022**, 77, 103905 0
- 73 Advances in Delivery of Selective Internal Radiation Therapy (SIRT): Economic and Logistical Effects of Same-Stay Work-Up and Procedure in the Treatment of Unresectable Liver Tumors in England. 0
- 72 Integrated analysis of ferroptosis-related gene signature for overall survival prediction in Asian patients with hepatocellular carcinoma. 0
- 71 Treatment patterns for hepatocellular carcinoma in patients with ChildBugh class B and their impact on survival: A Korean nationwide registry study. 2
- 70 Evolving therapeutic landscape of advanced hepatocellular carcinoma. 0
- 69 TACE plus PD-1 successfully achieves conversion therapy for unresectable HCC with multiple macrovascular invasion: a case report. 0
- 68 Prognostic analysis of hepatocellular carcinoma with macrovascular invasion after liver resection and a successful case of conversion therapy. 9, 0

67	Changing epidemiology of hepatocellular carcinoma in South America: a report from the South American liver research network. 2022 , 100876	0
66	Custom gene expression panel for evaluation of potential molecular markers in hepatocellular carcinoma. 2022 , 15,	1
65	Improving pain control during transarterial chemoembolization for hepatocellular carcinoma performed under local anesthesia with multimodal analgesia. 2022 ,	0
64	Lenvatinib plus immune checkpoint inhibitors or locoregional therapy in unresectable hepatocellular carcinoma: Lessons learned and moving forwards. 2023 , 1878, 188841	0
63	2022 KLCA-NCC Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. 2022 , 23, 1126	4
62	Transarterial Chemoembolization Combined with Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors versus Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Advanced Hepatocellular Carcinoma. Volume 9, 1217-1228	0
61	PAIP1 is a novel oncogene in human hepatocellular carcinoma. 2022 , 13,	0
60	Criteria for identifying potentially resectable patients with initially oncologically unresectable hepatocellular carcinoma before treatment with lenvatinib plus an antiPD1 antibody. 13,	0
59	Clinical-radiomics predictors to identify the suitability of transarterial chemoembolization treatment in intermediate-stage hepatocellular carcinoma: A multicenter study. 2022 ,	0
58	Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trial.	3
57	Early alpha-fetoprotein response predicts prognosis of immune checkpoint inhibitor and targeted therapy for hepatocellular carcinoma: a systematic review with meta-analysis. 1-11	0
56	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma.	0
55	Comparison of the Efficacy and Safety of Transarterial Chemoembolization Plus Microwave Ablation versus Surgical Resection in Patients with Solitary Large Hepatocellular Carcinoma: A Propensity Score-Matched Analysis. Volume 9, 1309-1321	0
54	An overview: Management of patients with advanced hepatocellular carcinoma. 2022 , 16, 405-425	0
53	Clinical practice guideline and real-life practice in hepatocellular carcinoma: Chinese perspective.	0
52	A Critical Role of the IL-22/IL-22 Binding Protein Axis in Hepatocellular Carcinoma. 2022 , 14, 6019	0
51	Association between sarcopenia and prognosis of hepatocellular carcinoma: A systematic review and meta-analysis. 9,	0
50	A six lipid metabolism related gene signature for predicting the prognosis of hepatocellular carcinoma. 2022 , 12,	0

- 49 Nivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 Trial. ○
- 48 Hepatectomy After Conversion Therapy for Initially Unresectable HCC: What is the Difference?. Volume 9, 1353-1368 ○
- 47 Prognostic model of immune checkpoint inhibitors combined with anti-angiogenic agents in unresectable hepatocellular carcinoma. 13, ○
- 46 Drug-eluting Microspheres Compared to Conventional Transarterial Chemoembolization as First Line Treatment for Unresectable Hepatocellular Carcinoma: A Single-center Retrospective Cost-utility Analysis. ○
- 45 Liver Cancer: Interdisciplinary Approach. **2022**, ○
- 44 Cellular and Molecular Biology of Cancer Stem Cells of Hepatocellular Carcinoma. **2023**, 24, 1417 ○
- 43 Prognostic Value of a CT Radiomics-Based Nomogram for the Overall Survival of Patients with Nonmetastatic BCLC Stage C Hepatocellular Carcinoma after Stereotactic Body Radiotherapy. **2023**, 2023, 1-12 ○
- 42 A pyroptosis-related gene signature provides an alternative for predicting the prognosis of patients with hepatocellular carcinoma. **2023**, 16, ○
- 41 A novel m7G-related signature to predict prognosis and immune status in patients with hepatocellular carcinoma. ○
- 40 A Single Nucleotide Polymorphism rs1010816 Predicts Sorafenib Therapeutic Outcomes in Advanced Hepatocellular Carcinoma. **2023**, 24, 1681 ○
- 39 Development and validation of a mitochondrial energy metabolism-related risk model in hepatocellular carcinoma. **2023**, 855, 147133 ○
- 38 Secular Trends of Clinical Characteristics and Survival of Hepatocellular Carcinoma in Taiwan from 2011 to 2019. **2023**, 15, 126 1
- 37 Selective internal radiation therapy with yttrium-90 resin microspheres followed by anatomical hepatectomy: A potential curative strategy in advanced hepatocellular carcinoma. ○
- 36 Life expectancy of patients with hepatocellular carcinoma according to the upfront treatment: A nationwide analysis. **2023**, ○
- 35 Difficulties for providing evidence in hepatocellular carcinoma with Child-Pugh B liver function. **2023**, 43, 274-275 ○
- 34 Cost-utility analysis of atezolizumab with bevacizumab in untreated unresectable or advanced hepatocellular carcinoma in France. **2023**, 18, e0280442 ○
- 33 Sarcopenia indicate poor survival in patients undergoing transarterial chemoembolization (TACE) for hepatic malignancies. ○
- 32 Evaluation and Prediction of Treatment Response for Hepatocellular Carcinoma. **2023**, 22, 209-220 ○

31	Intravoxel incoherent motion diffusion weighted imaging for preoperative evaluation of liver regeneration after hepatectomy in hepatocellular carcinoma.	○
30	ncRNA-mediated fatty acid metabolism reprogramming in HCC. 2023 , 34, 278-291	○
29	Research Progress and Prospects of Conversion Therapy for Primary Liver Cancer. 2022 , 12, 11680-11685	○
28	The neutrophil-to-lymphocyte ratio at the start of the second course during atezolizumab plus bevacizumab therapy predicts therapeutic efficacy in patients with advanced hepatocellular carcinoma: A multicenter analysis.	○
27	Vascular endothelial growth factor A is a potential prognostic biomarker and correlates with immune cell infiltration in hepatocellular carcinoma. 2023 , 27, 538-552	○
26	Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001). 2023 , 8,	○
25	Sintilimab plus Lenvatinib conversion therapy for intermediate/locally advanced hepatocellular carcinoma: A phase 2 study. 13,	○
24	Comparison of CalliSpheres [®] microspheres drug-eluting beads and conventional transarterial chemoembolization in hepatocellular carcinoma patients: a randomized controlled trial. 2023 , 57, 70-79	○
23	FOXA2 plays a critical role in hepatocellular carcinoma progression and lenvatinib-associated drug resistance. 2023 ,	○
22	Chemerin and Chemokine-like Receptor 1 Expression Are Associated with Hepatocellular Carcinoma Progression in European Patients. 2023 , 11, 737	1
21	Effect of Preoperative Treatment on Survival of Patients with Hepatocellular Carcinoma after Liver Transplantation. 2023 , 13, 2903-2910	○
20	Hepatic Dystrophic Calcification Secondary to Transarterial Chemoembolization: Case Report and Review of Literature. 2023 ,	○
19	Radiomics models based on multisequence MRI for prediction of PD-1/PD-L1 expression in hepatocellular carcinoma.	○
18	The treatment of transarterial chemoembolization/hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitor is effective against hepatocellular carcinoma with portal vein tumor thrombus: A systematic review. 13,	○
17	Postoperative adjuvant transarterial chemoembolisation improves survival of hepatocellular carcinoma patients with microvascular invasion: A multicenter retrospective cohort. 2023 , 11, 228-241	○
16	Risk Factors of Complications from Central Bisectionectomy (H458) for Hepatocellular Carcinoma: A Multi-Institutional Single-Arm Analysis. 2023 , 15, 1740	○
15	Rs9679162 genotype predicts prognosis of real-world advanced hepatocellular carcinoma treated by sorafenib. 2023 , 36, 251-266	○
14	Management of hepatocellular carcinoma in China: Seeking common grounds while reserving differences. 2023 , 29, 342-344	○

- 13 Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment. ○
- 12 Alcoholic Liver Disease-Related Hepatocellular Carcinoma: Characteristics and Comparison to General Slovak Hepatocellular Cancer Population. **2023**, 30, 3557-3570 ○
- 11 Impact of NOTCH1 polymorphisms on liver cancer in a Chinese Han population. **2023**, 22, 1127-1134 ○
- 10 Management of hepatocellular carcinoma from diagnosis in routine clinical practice. **2022**, 9, ○
- 9 Efficacy of Radiation Plus Transarterial Chemoembolization and Lenvatinib in Hepatocellular Carcinoma With Portal Vein Tumor Thrombus. ○
- 8 Stage migration as a surrogate of survival in hepatocellular carcinoma treated with transarterial chemoembolization. **2023**, 7, ○
- 7 Chromosome 11q13 amplification correlates with poor response and prognosis to PD-1 blockade in unresectable hepatocellular carcinoma. 14, ○
- 6 Role of sex in liver tumor occurrence and clinical outcomes: a comprehensive review. Publish Ahead of Print, ○
- 5 Efficacy of adjuvant TACE on the prognosis of patients with HCC after hepatectomy: a multicenter propensity score matching from China. **2023**, 23, ○
- 4 Kaempferol induces DNA damage, cell apoptosis and cell cycle arresting by promoting DNA-PKcs ubiquitination degradation in Bel-7402/5-Fu cells. ○
- 3 A Novel Neutrophil-to-Lymphocyte Ratio and Sarcopenia Based TACE-Predict Model of Hepatocellular Carcinoma Patients. Volume 10, 659-671 ○
- 2 Anti-PD-1 therapy achieves favorable outcomes in HBV-positive non-liver cancer. **2023**, 12, ○
- 1 Thioredoxin facilitates hepatocellular carcinoma stemness and metastasis by increasing BACH1 stability to activate the AKT / mTOR pathway. **2023**, 37, ○